Pharmaceutical Products
Code 30 (Harmonized System 2012 by 2 digits)
2024: US$11.5B, Total Trade Exchange
2024: US$2.73B, International Sales
2024: US$8.8B, International Purchases
Code 30 (Harmonized System 2012 by 2 digits)
2024: US$11.5B, Total Trade Exchange
2024: US$2.73B, International Sales
2024: US$8.8B, International Purchases
In 2024, the trade exchange (includes international purchases and sales) of Pharmaceutical Products was US$11.5B.
In 2024, the states with the most international sales in Pharmaceutical Products were Ciudad de México (US$1.38B), Morelos (US$345M), Estado de México (US$333M), Jalisco (US$276M), and Chihuahua (US$118M).
The states with the most international purchases in 2024 were Ciudad de México (US$6.74B), Estado de México (US$1.04B), Chihuahua (US$236M), Jalisco (US$225M), and Baja California (US$181M).
In 2024, the main commercial destinations of Pharmaceutical Products were United States (US$1.34B), Colombia (US$261M), Canada (US$234M), Panama (US$133M), and Brazil (US$93.2M).
The main commercial origins of Pharmaceutical Products in 2024 were United States (US$1.56B), Germany (US$1.35B), Puerto Rico (US$656M), France (US$638M), and Switzerland (US$617M).
In the global context, the main exporting countries of Pharmaceutical Products in 2022 were Germany (US$123B), United States (US$93.6B), and Ireland (US$86.3B). In the same year, the main importing countries of Pharmaceutical Products were United States (US$163B), Germany (US$77B), and Switzerland (US$48.3B).
US$11.5B, Total Trade Exchange (2024)
In 2024, the total trade exchange of Pharmaceutical Products in Mexico (including international purchases and sales) was US$11.5B.
The visualizations show the net balance of Pharmaceutical Products at the level of states and countries. Colors more similar to blue, indicate that the territory presented a higher level of international sales. Colors more similar to red, indicate that the territory presented a higher level of international purchases.
March, 2025
In March 2025, international sales of Pharmaceutical Products were US$218M and a total of US$776M in international purchases. For this month the net trade balance of Pharmaceutical Products it was of -US$558M.
2025-Q1: US$554M, International Sales
The visualization shows the quarterly concentration of international sales of Pharmaceutical Products at state level.
In the first quarter of 2025, international sales were US$554M, being the states with the most sales Ciudad de México (US$303M), Jalisco (US$60.6M), and Estado de México (US$48M).
Ciudad de México: US$1.38B, State with the Most International Sales (2024)
United States: US$1.34B, Main commercial destination (2024)
In 2024, the states with the highest international sales in Pharmaceutical Products were Ciudad de México (US$1.38B), Morelos (US$345M), Estado de México (US$333M), Jalisco (US$276M), and Chihuahua (US$118M).
In 2024, the countries with the most international purchases from Mexico were United States (US$1.34B), Colombia (US$261M), Canada (US$234M), Panama (US$133M), and Brazil (US$93.2M).
Ciudad de México: US$6.74B, State with the Most International Purchases (2024)
United States: US$1.56B, Main Commercial Origin (2024)
In 2024, the states with the highest international in Pharmaceutical Products were Ciudad de México (US$6.74B), Estado de México (US$1.04B), Chihuahua (US$236M), Jalisco (US$225M), and Baja California (US$181M).
The countries with the most international sales to Mexico in 2024 were United States (US$1.56B), Germany (US$1.35B), Puerto Rico (US$656M), France (US$638M), and Switzerland (US$617M).
The RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Pharmaceutical Products and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Pharmaceutical Products. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
The visualizations show the global market for Pharmaceutical Products. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Pharmaceutical Products were Germany (US$123B), United States (US$93.6B), and Ireland (US$86.3B). In the same year, the main importing countries for Pharmaceutical Products were United States (US$163B), Germany (US$77B), and Switzerland (US$48.3B).